Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

Devalingam Mahalingam, Manish R. Patel, Jasgit C. Sachdev, Lowell L. Hart, Niels Halama, Ramesh K. Ramanathan, John Sarantopoulos, Dirk Völkel, Ashraf Youssef, Floris A. de Jong, Apostolia Maria Tsimberidou*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science